GlassScriptPhysician profile
Shymol Aji John
NPI 1679115703
$13,844.93
in general payments reported to CMS, 2019-2025
35 companies · $7,473 in 2025
The $7,473 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $177 · 2022: $723 · 2023: $1,731 · 2024: $3,740 · 2025: $7,473.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $2,640 · Education: $126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,179.34 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $2,640.00 |
| Education | $125.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $2,969.53 | 2023-2025 | Ocaliva |
| Abbvie INC. | $2,938.23 | 2022-2025 | |
| Madrigal Pharmaceuticals | $978.78 | 2024-2025 | Rezdiffra, Resmetirom |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $954.58 | 2022-2025 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $903.57 | 2022-2025 | Tremfya, Stelara |
| Genzyme Corporation | $764.25 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $406.43 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $405.78 | 2022-2025 | Entyvio, Eohilia |
| Gilead Sciences, INC. | $398.56 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $370.15 | 2021-2025 | Dupixent |
| Ardelyx, INC. | $316.42 | 2023-2025 | Ibsrela |
| Ipsen Biopharmaceuticals, INC | $284.40 | 2024-2025 | Iqirvo |
| Qol Medical, LLC | $268.09 | 2022-2025 | Sucraid, Sucraid |
| Lilly USA, LLC | $225.80 | 2024-2025 | Omvoh |
| Ironwood Pharmaceuticals, INC | $208.97 | 2023-2024 | Linzess |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Enterra Medical, INC. | $162.69 | 2024 | |
| Novo Nordisk INC | $158.67 | 2025 | Wegovy |
| Janssen Scientific Affairs, LLC | $142.27 | 2024-2025 | Stelara, Tremfya |
| Celltrion USA INC. | $130.04 | 2025 | Vegzelma |
| Phathom Pharmaceuticals, INC. | $120.87 | 2025 | Voquezna |
| Aimmune Therapeutics, INC. | $98.97 | 2024-2025 | Zenpep, Vowst |
| E.R. Squibb & Sons, L.L.C. | $97.76 | 2023 | Zeposia |
| Celgene Corporation | $88.92 | 2023-2024 | Zeposia |
| Pfizer INC. | $81.36 | 2023-2025 | |
| Organon LLC | $66.10 | 2024 | |
| Blueprint Medicines Corporation | $51.54 | 2025 | Ayvakit |
| Merck Sharp & Dohme LLC | $47.07 | 2024 | Dificid |
| Mallinckrodt Hospital Products INC. | $43.86 | 2024 | Terlivaz |
| Actelion Pharmaceuticals US, INC. | $37.10 | 2022 | |
| Harmony Biosciences LLC | $22.74 | 2022 | |
| Tersera Therapeutics LLC | $22.68 | 2023 | Xermelo |
| Genentech USA, INC. | $22.25 | 2023 | Tecentriq |
| Sanofi-Aventis U.S. LLC | $20.09 | 2025 | |
| Pharmacosmos Therapeutics INC. | $18.82 | 2024 | Monoferric |
| Vyera Pharmaceuticals, LLC | $17.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shymol John listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.